Document:

EX-10.5

 Exhibit 10.5 
 INDEMNIFICATION AGREEMENT 
 THIS INDEMNIFICATION AGREEMENT (this
“Agreement”), dated as of                  , is made by and between Mallinckrodt Brand Pharmaceuticals, Inc., a Delaware corporation (“Brand
Pharma”), and                  (“Indemnitee”). 
 WHEREAS, Brand Pharma is a wholly owned subsidiary of Mallinckrodt plc; 
 WHEREAS,
it is essential to Brand Pharma and Mallinckrodt plc that Mallinckrodt plc retain and attract as directors and secretary the most capable persons available; 
 WHEREAS, Brand Pharma has requested that the Indemnitee serve as a director, officer, secretary or employee of Mallinckrodt plc, and, if requested to do so by Brand Pharma, as a director, officer,
secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise; and 

WHEREAS, each of Mallinckrodt plc, Brand Pharma and Indemnitee recognize the increased risk of litigation and other claims currently
being asserted against directors and officers of companies; 
 WHEREAS, due to restrictions imposed by Irish law, the Articles
of Association of Mallinckrodt plc do not confer indemnification and advancement rights on its directors and secretary as broad as the indemnification and advancement rights that are customarily provided to the directors and secretary of a company
organized under the laws of a U.S. state; 
 WHEREAS, in recognition of Indemnitee’s need for (i) substantial
protection against personal liability, (ii) specific contractual assurance that such protection will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of Mallinckrodt plc’s Articles of
Association, the certificate of incorporation or bylaws of Brand Pharma (the “Brand Pharma Organizational Documents”) or any change in the composition of Mallinckrodt plc’s Board of Directors or acquisition transaction relating to
Mallinckrodt plc), Brand Pharma wishes to provide in this Agreement for the indemnification by Brand Pharma of and the advancing by Brand Pharma of expenses to Indemnitee as set forth in this Agreement; 

NOW, THEREFORE, in consideration of the above premises and of Indemnitee continuing to serve Mallinckrodt plc directly or, at Brand
Pharma’s request, with another Enterprise, and intending to be legally bound hereby, the parties agree as follows: 
 1. Certain
Definitions. 
 (a) Affiliate: any corporation or other person or entity that directly, or indirectly through one or more
intermediaries, controls or is controlled by, or is under common control with, the person specified. 
 (b) Board: the Board of Directors
of Mallinckrodt plc. 

 (c) Change in Control: shall be deemed to have occurred if: 

(i) any “person,” as such term is used in Sections 3(a)(9) and 13(d) of the Exchange Act, becomes a “beneficial
owner,” as such term is used in Rule 13d-3 promulgated under the Exchange Act, of 50% or more of the Voting Shares (as defined below) of Mallinckrodt plc; 
 (ii) the majority of the Board consists of individuals other than Incumbent Directors, which term means the members of the Board as of the execution hereof, provided that any person becoming a director
subsequent to such time whose election or nomination for election was supported by three-quarters of the directors who immediately prior to such election or nomination for election comprised the Incumbent Directors shall be considered to be an
Incumbent Director; 
 (iii) Mallinckrodt plc adopts any plan of liquidation providing for the distribution of all or
substantially all of its assets; 
 (iv) all or substantially all of the assets or business of Mallinckrodt plc is disposed of
pursuant to a merger, consolidation or other transaction (unless the shareholders of Mallinckrodt plc immediately prior to such a merger, consolidation or other transaction beneficially own, directly or indirectly, in substantially the same
proportion as they owned the Voting Shares of Mallinckrodt plc, all of the Voting Shares or other ownership interests of the entity or entities, if any, that succeed to the business of Mallinckrodt plc); or 

(v) Mallinckrodt plc combines with another company and is the surviving entity but, immediately after the combination, the shareholders
of Mallinckrodt plc immediately prior to the combination hold, directly or indirectly, 50% or less of the Voting Shares of the combined company (there being excluded from the number of shares held by such shareholders, but not from the Voting Shares
of the combined company, any shares received by Affiliates of such other company in exchange for shares of such other company), provided, however, that any occurrence that would, in the absence of this proviso, otherwise constitute a Change in
Control pursuant to any of clause (i), (iii), (iv) or (v) above, shall not constitute a Change in Control if such occurrence is approved by a majority of the directors on the Board who were directors immediately prior to such occurrence.

 (d) Enterprise: Mallinckrodt plc and any other corporation, limited liability company, partnership, joint venture, trust, employee
benefit plan or other enterprise of which Indemnitee is or was serving at the request of Brand Pharma as a director, officer, secretary, trustee, general partner, managing member, fiduciary, board of directors’ committee member, employee or
agent. 
 (e) Exchange Act: the U.S. Securities Exchange Act of 1934, as amended. 

(f) Expenses: any expense, liability, or loss, including attorneys’ fees, judgments, fines, ERISA excise taxes and penalties, amounts paid or
to be paid in settlement, any interest, assessments, or other charges imposed thereon, any federal, state, local, or foreign taxes imposed as a result of the actual or deemed receipt of any payments under this Agreement, and all other costs and
obligations, paid or incurred in connection with investigating, defending, prosecuting (subject to Section 2(b)), being a witness in, participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding relating to
any Indemnifiable Event. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond,
or other appeal bond or its equivalent. 

  
 - 2 -

 (g) Indemnifiable Event: any event or occurrence that takes place either prior to or after the
execution of this Agreement, related to the fact that Indemnitee is or was a director, officer, secretary or employee of Mallinckrodt plc, or while a director or secretary of Mallinckrodt plc is or was serving at the request of Brand Pharma as a
director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or
not done by Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a
director, officer, secretary, employee, trustee, agent, or fiduciary. 
 (h) Independent Counsel: the meaning specified in
Section 3. 
 (i) Proceeding: any threatened, pending, or completed action, suit, or proceeding or any alternative dispute
resolution mechanism (including an action by or in the right of Mallinckrodt plc), or any inquiry, hearing, or investigation, whether conducted by Mallinckrodt plc or any other party, that Indemnitee in good faith believes might lead to the
institution of any such action, suit, or proceeding, whether civil, criminal, administrative, investigative, or other. 
 (j) Reviewing
Party: the meaning specified in Section 3. 
 (k) Voting Shares: shares of any class or classes having general voting power
under ordinary circumstances, in the absence of contingencies, to elect the directors (or similar function) of an Enterprise. 
 2. Agreement
to Indemnify. 
 (a) General Agreement. In the event Indemnitee was, is, or becomes a party to or witness or other participant in, or
is threatened to be made a party to or witness or other participant in, a Proceeding by reason of (or arising in part out of) an Indemnifiable Event, Brand Pharma shall indemnify Indemnitee from and against any and all Expenses to the fullest extent
permitted by law, as the same exists or may hereafter be amended or interpreted (but in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits Brand Pharma to provide broader
indemnification rights than were permitted prior thereto). The parties hereto intend that this Agreement shall provide for indemnification in excess of that expressly permitted by statute or provided by Mallinckrodt plc’s Articles of
Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents or applicable law. 
 (b) Initiation of Proceeding. Notwithstanding anything in this Agreement to the contrary, Indemnitee shall not be entitled to indemnification pursuant to this Agreement in connection with any
Proceeding initiated by Indemnitee against Mallinckrodt plc or any of its subsidiaries or any director, officer or employee of Mallinckrodt plc or any of its subsidiaries unless (i) Mallinckrodt plc has joined in or the Board has consented to
the initiation of such Proceeding; (ii) the Proceeding is one to enforce indemnification rights under Section 4; or (iii) the Proceeding is instituted after a Change in Control and Independent Counsel has approved its initiation.

  
 - 3 -

 (c) Expense Advances. If so requested by Indemnitee, Brand Pharma shall advance (within five
business days of such request) any and all Expenses to Indemnitee (an “Expense Advance”); provided that, (i) such Expense Advance shall be made only upon delivery to Brand Pharma of an undertaking by or on behalf of the Indemnitee to
repay the amount thereof if it is ultimately determined that Indemnitee is not entitled to be indemnified by Brand Pharma, (ii) Brand Pharma shall not (unless a court of competent jurisdiction shall determine otherwise) be required to make an
Expense Advance if and to the extent that the Reviewing Party has determined that Indemnitee is not permitted to be indemnified under applicable law, and (iii) if and to the extent that the Reviewing Party determines after payment of one or
more Expense Advances that Indemnitee would not be permitted to be so indemnified under applicable law, Brand Pharma shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse Brand Pharma) for all such amounts theretofore
paid. If Indemnitee has commenced or commences legal proceedings in a court of competent jurisdiction or commences arbitration to secure a determination that Indemnitee is entitled to indemnification or Expense Advance, as provided in
Section 4, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding, and Indemnitee shall not be required to reimburse Brand Pharma for any Expense Advance
until a final determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or have lapsed). Indemnitee’s obligation to reimburse Brand Pharma for Expense Advances shall be unsecured and no interest
shall be charged thereon. 
 (d) Mandatory Indemnification. Notwithstanding any other provision of this Agreement, to the extent that
Indemnitee has been successful on the merits or otherwise in defense of any Proceeding relating in whole or in part to an Indemnifiable Event or in defense of any issue or matter therein, Indemnitee shall be indemnified by Brand Pharma hereunder
against all Expenses incurred in connection therewith. 
 (e) Partial Indemnification. If Indemnitee is entitled under any provision of
this Agreement to indemnification by Brand Pharma for some or a portion of Expenses, but not, however, for the total amount thereof, Brand Pharma shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 (f) Prohibited Indemnification. No indemnification pursuant to this Agreement shall be paid by Brand Pharma: 

(i) on account of any Proceeding in which a final and non-appealable judgment is rendered against Indemnitee for an accounting of profits
made from the purchase or sale by Indemnitee of securities of Mallinckrodt plc pursuant to the provisions of Section 16(b) of the Exchange Act or similar provisions of any federal, state, or local laws; 

(ii) if a court of competent jurisdiction by a final and non-appealable judgment, shall determine that such indemnification is not
permitted under applicable law; 

  
 - 4 -

 (iii) on account of any Proceeding relating to an Indemnifiable Event as to which the
Indemnitee has been convicted of a crime constituting a felony under the laws of the jurisdiction where the criminal action had been brought (or, where a jurisdiction does not classify any crime as a felony, a crime for which Indemnitee is sentenced
to death or imprisonment for a term exceeding one year); or 
 (iv) on account of any Proceeding brought by Mallinckrodt plc or
any of its subsidiaries against Indemnitee. 
 3. Reviewing Party; Exhaustion of Remedies.

(a) Prior to any Change in Control, the reviewing party (the “Reviewing Party”) shall be any appropriate person or body consisting of a member
or members of the Board or any other person or body appointed by the Board who is not a party to the particular Proceeding with respect to which Indemnitee is seeking indemnification; after a Change in Control, the Independent Counsel referred to
below shall become the Reviewing Party. With respect to all matters arising after a Change in Control concerning the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement, the separate deed of indemnification which
Indemnitee has with Mallinckrodt plc or any other agreement to which Mallinckrodt plc or any of its Affiliates is a party or under applicable law, Mallinckrodt plc’s Articles of Association or the Brand Pharma Organizational Documents now or
hereafter in effect relating to indemnification for Indemnifiable Events, Mallinckrodt plc and Brand Pharma shall seek legal advice only from independent counsel (“Independent Counsel”) selected by Indemnitee and approved by Mallinckrodt
plc (which approval shall not be unreasonably withheld), and who has not otherwise performed services for Mallinckrodt plc, Brand Pharma or the Indemnitee (other than in connection with indemnification matters) within the last five years. The
Independent Counsel shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing Mallinckrodt plc, Brand Pharma or Indemnitee in an action to determine
Indemnitee’s rights under this Agreement. Such counsel, among other things, shall render its written opinion to Mallinckrodt plc, Brand Pharma and Indemnitee as to whether and to what extent the Indemnitee should be permitted to be indemnified
under applicable law. In doing so, the Independent Counsel may consult with (and rely upon) counsel in any appropriate jurisdiction who would qualify as Independent Counsel (“Local Counsel”). Brand Pharma agrees to pay the reasonable fees
of the Independent Counsel and the Local Counsel and to indemnify fully such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, loss, and damages arising out of or relating to this Agreement or the engagement
of Independent Counsel or the Local Counsel pursuant hereto. 
 (b) Prior to making written demand on Brand Pharma for indemnification pursuant
to Section 4(a) or making a request for Expense Advance pursuant to Section 2(c), Indemnitee shall (i) seek such indemnification or Expense Advance, as applicable, under any applicable insurance policy and (ii) request that
Mallinckrodt plc consider in its discretion whether to make such indemnification or Expense Advance, as applicable. Upon any such request by Indemnitee of Mallinckrodt plc, Mallinckrodt plc shall consider whether to make such indemnification or
Expense Advance, as applicable, based on the facts and circumstances related to the request. Mallinckrodt plc may require, as a condition to making any indemnification or Expense Advance, as applicable, that Indemnitee enter into an agreement
providing for such indemnification or Expense 

  
 - 5 -

 
Advance, as applicable, to be made subject to substantially the same terms and conditions applicable to an indemnification or Expense Advance, as applicable, by Brand Pharma hereunder (including,
without limitation, conditioning any Expense Advance upon delivery to Mallinckrodt plc of an undertaking of the type described in clause (i) of the proviso to Section 2(c)). In the event indemnification or Expense Advance, as applicable,
is not received pursuant to an insurance policy, or from Mallinckrodt plc, within 5 business days of the later of Indemnitee’s request of the insurer and Indemnitee’s request of Mallinckrodt plc as provided in the first sentence of this
Section 3(b), Indemnitee may make written demand on Brand Pharma for indemnification pursuant to Section 4(a) or make a request for Expense Advance pursuant to Section 2(c), as applicable. 

4. Indemnification Process and Appeal. 

(a) Indemnification Payment. Indemnitee shall be entitled to indemnification of Expenses, and shall receive payment thereof, from Brand Pharma in
accordance with this Agreement as soon as practicable after Indemnitee has made written demand on Brand Pharma for indemnification, unless the Reviewing Party has given a written opinion to Brand Pharma that Indemnitee is not entitled to
indemnification under applicable law. 
 (b) Adjudication or Arbitration. (i) Regardless of any action by the Reviewing Party, if
Indemnitee has not received full indemnification or Expense Advance to which Indemnitee is entitled hereunder within thirty days after making a demand or request in accordance with Section 4(a) or Section 2(c), as applicable (a
“Nonpayment”), Indemnitee shall have the right to enforce its indemnification rights under this Agreement by commencing litigation in any federal or state court located in the State of Delaware (a “Delaware Court”) having subject
matter jurisdiction thereof seeking an initial determination by the court or by challenging any determination by the Reviewing Party or any aspect thereof. Any determination by the Reviewing Party not challenged by Indemnitee in any such litigation
shall be binding on Mallinckrodt plc, Brand Pharma and Indemnitee. The remedy provided for in this Section 4 shall be in addition to any other remedies available to Indemnitee at law or in equity. Mallinckrodt plc, Brand Pharma and Indemnitee
hereby irrevocably and unconditionally (A) consent to submit to the non-exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (B) waive any objection to
the laying of venue of any such action or proceeding in the Delaware Court, and (C) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or
inconvenient forum. For the avoidance of doubt, nothing in this Agreement shall limit any right Indemnitee may have under applicable law to bring any action or proceeding in any other court. 

(ii) Alternatively, in the case of a Nonpayment, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a
single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. 
 (iii) In the event
that a determination shall have been made pursuant to Section 4(a) or 2(c) of this Agreement that Indemnitee is not entitled to indemnification or Expense Advance, any judicial proceeding or arbitration commenced pursuant to this
Section 4(b) shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced

  
 - 6 -

 
pursuant to this Section 4(b) Brand Pharma shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. If Indemnitee
commences a judicial proceeding or arbitration pursuant to this Section 4(b), Indemnitee shall not be required to reimburse Brand Pharma for any advances pursuant to Section 2(c) until a final determination is made with respect to
Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). 
 (iv) In
the event that Indemnitee, pursuant to this Section 4(b), seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, and it is determined in said judicial
adjudication or arbitration that Indemnitee is entitled to receive all of the indemnification or advancement of Expenses sought, Indemnitee shall be entitled to recover from Brand Pharma, and shall be indemnified by Brand Pharma against, any and all
Expenses actually and reasonably incurred by him in such judicial adjudication or arbitration. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or
advancement of Expenses sought, the Indemnitee shall be entitled to recover from Brand Pharma, and shall be indemnified by Brand Pharma against, any and all Expenses reasonably incurred by Indemnitee in connection with such judicial adjudication or
arbitration. 
 (c) Defense to Indemnification, Burden of Proof, and Presumptions. (i) It shall be a defense to any action brought
by Indemnitee against Brand Pharma to enforce this Agreement that it is not permissible under applicable law for Brand Pharma to indemnify Indemnitee for the amount claimed. 
 (ii) In connection with any action or any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proving such a defense or
determination shall be on Brand Pharma. 
 (iii) Neither the failure of the Reviewing Party to have made a determination prior
to the commencement of such action by Indemnitee that indemnification of the Indemnitee is proper under the circumstances because Indemnitee has met the standard of conduct set forth in applicable law, nor an actual determination by the Reviewing
Party that the Indemnitee had not met such applicable standard of conduct, shall, of itself, be a defense to the action or create a presumption that the Indemnitee has not met the applicable standard of conduct. 

(iv) For purposes of this Agreement, to the fullest extent permitted by law, the termination of any claim, action, suit, or proceeding,
by judgment, order, settlement (whether with or without court approval), conviction, or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not meet any particular standard of conduct or
have any particular belief or that a court has determined that indemnification is not permitted by applicable law. 
 (v) For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of any Enterprise, including financial statements, or on information supplied
to Indemnitee by the management of such Enterprise in the course of their duties, or on the advice of legal counsel for such Enterprise or on information or records given or reports made to such Enterprise by an

  
 - 7 -

 
independent certified public accountant or by an appraiser or other expert selected by such Enterprise. The provisions of this Section 4(c)(v) shall not be deemed to be exclusive or to limit
in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in applicable law. 
 (vi) The knowledge and/or actions, or failure to act, of any other director, trustee, partner, managing member, fiduciary, officer, agent or employee of any Enterprise shall not be imputed to Indemnitee
for purposes of determining any right to indemnification under this Agreement. 
 (vii) Brand Pharma shall be precluded from
asserting in any judicial proceeding or arbitration commenced pursuant to this Agreement that the procedures or presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any court or before any arbitrator that
Brand Pharma is bound by all the provisions of this Agreement. 
 5. Indemnification for Expenses Incurred in Enforcing Rights. In
addition to Indemnitee’s rights under Section 4(b)(iv), Brand Pharma shall indemnify Indemnitee against any and all Expenses that are incurred by Indemnitee in connection with any action brought by Indemnitee: 

(a) for indemnification or advance payment of Expenses under any agreement to which Brand Pharma or any of its Affiliates is a party (other than this
Agreement) or under applicable law, Mallinckrodt plc’s Articles of Association or the Brand Pharma Organizational Documents now or hereafter in effect relating to indemnification or advance payment of Expenses for Indemnifiable Events (it being
specified, for the avoidance of doubt, that this clause (a) shall not be deemed to provide Indemnitee with a right to the indemnification or advance payment of Expenses being sought in such action), and/or 

(b) for recovery under directors’ and officers’ liability insurance policies maintained by Mallinckrodt plc, 

but, in either case, only in the event that Indemnitee ultimately is determined to be entitled to such indemnification or expense advance or insurance
recovery, as the case may be. In addition, Brand Pharma shall, if so requested by Indemnitee, advance the foregoing Expenses and any Expenses incurred in any action brought pursuant to Section 4 to Indemnitee, subject to and in accordance with
Section 2(c). 
 6. Notification and Defense of Proceeding. 
 (a) Notice. Promptly after receipt by Indemnitee of notice of the commencement of any Proceeding, Indemnitee shall, if a claim in respect thereof is to be made against Brand Pharma under this
Agreement, notify Mallinckrodt plc and Brand Pharma of the commencement thereof; but the omission so to notify Mallinckrodt plc and Brand Pharma will not relieve Brand Pharma from any liability that it may have to Indemnitee, except as provided in
Section 6(c). 
 (b) Defense. With respect to any Proceeding as to which Indemnitee notifies Mallinckrodt plc and Brand Pharma of
the commencement thereof, Brand Pharma will be entitled to participate in the Proceeding at its own expense and except as otherwise provided below, to the extent Brand Pharma so wishes, it may assume the defense thereof with counsel reasonably
satisfactory to Indemnitee. After notice from Brand Pharma to Indemnitee of its election to assume the defense of 

  
 - 8 -

 
any Proceeding, Brand Pharma shall not be liable to Indemnitee under this Agreement or otherwise for any Expenses subsequently incurred by Indemnitee in connection with the defense of such
Proceeding other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the right to employ legal counsel in such Proceeding, but all Expenses related thereto incurred after notice from Brand Pharma of its
assumption of the defense shall be at Indemnitee’s expense unless: (i) the employment of legal counsel by Indemnitee has been authorized by Brand Pharma, (ii) Indemnitee has reasonably determined that there may be a conflict of
interest between Indemnitee and Brand Pharma in the defense of the Proceeding, (iii) after a Change in Control, the employment of counsel by Indemnitee has been approved by the Independent Counsel, or (iv) Brand Pharma shall not in fact
have employed counsel to assume the defense of such Proceeding, in each of which cases all Expenses of the Proceeding shall be borne by Brand Pharma. Brand Pharma shall not be entitled to assume the defense of any Proceeding (x) brought by or
on behalf of Mallinckrodt plc or Brand Pharma, (y) as to which Indemnitee shall have made the determination provided for in (ii) above or (z) after a Change in Control (it being specified, for the avoidance of doubt, that Brand Pharma
may assume defense of any such proceeding described in this sentence with Indemnitee’s consent, provided that any such consent shall not affect the rights of Indemnitee under the foregoing provisions of this Section 6(b)). 

(c) Settlement of Claims. Brand Pharma shall not be liable to indemnify Indemnitee under this Agreement or otherwise for any amounts paid in
settlement of any Proceeding effected without Brand Pharma’s written consent, such consent not to be unreasonably withheld; provided, however, that if a Change in Control has occurred, Brand Pharma shall be liable for indemnification of
Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Brand Pharma shall not settle any Proceeding in any manner that would impose any penalty or limitation on Indemnitee without Indemnitee’s written
consent. Brand Pharma shall not be liable to indemnify the Indemnitee under this Agreement with regard to any judicial award if Brand Pharma was not given a reasonable and timely opportunity, at its expense, to participate in the defense of such
action; Brand Pharma’s liability hereunder shall not be excused if assumption of the defense of the Proceeding by Brand Pharma was barred by this Agreement. 
 7. Establishment of Trust. In the event of a Change in Control Brand Pharma shall, upon written request by Indemnitee, create a trust for the benefit of the Indemnitee (the “Trust”) and
from time to time upon written request of Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Expenses reasonably anticipated at the time of each such request (a) to be incurred in connection with investigating,
preparing for, participating in, and/or defending any Proceeding relating to an Indemnifiable Event and (b) to be indemnifiable pursuant to this Agreement. The amount or amounts to be deposited in the Trust pursuant to the foregoing funding
obligation shall be determined by the Independent Counsel. The terms of the Trust shall provide that (i) the Trust shall not be revoked or the principal thereof invaded without the written consent of the Indemnitee, (ii) the Trustee (as
defined below) shall advance, within five business days of a request by the Indemnitee, any and all Expenses to the Indemnitee on the same terms and conditions as provided in Section 2(c) (and the Indemnitee hereby agrees to reimburse the Trust
under the same circumstances for which the Indemnitee would be required to reimburse Brand Pharma under Section 2(c) of this Agreement), (iii) the Trust shall continue to be funded by Brand Pharma in accordance with the funding obligation
set forth above, (iv) the Trustee shall promptly pay to the Indemnitee all amounts for which the Indemnitee shall be entitled to indemnification pursuant to this Agreement, and (v) all unexpended funds in the Trust shall revert to

  
 - 9 -

 
Brand Pharma upon a final determination by the Independent Counsel or a court of competent jurisdiction, as the case may be, that the Indemnitee has been fully indemnified under the terms of this
Agreement. The trustee of the Trust (the “Trustee”) shall be chosen by the Indemnitee. Nothing in this Section 7 shall relieve Brand Pharma of any of its obligations under this Agreement. All income earned on the assets held in the
Trust shall be reported as income by Brand Pharma for federal, state, local, and foreign tax purposes. Brand Pharma shall pay all costs of establishing and maintaining the Trust and shall indemnify the Trustee against any and all expenses (including
attorney’s fees), claims, liabilities, loss, and damages arising out of or relating to this Agreement or the establishment and maintenance of the Trust. 
 8. Non-Exclusivity. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under Mallinckrodt plc’s Articles of Association, the separate deed of
indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents, applicable law or otherwise. To the extent that a change in applicable law (whether by statute or judicial decision) permits greater
indemnification than would be afforded currently under Mallinckrodt plc’s Articles of Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc, the Brand Pharma Organizational Documents, applicable law or
this Agreement, it is the intent of the parties that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change.
 9.
Continuation of Contractual Indemnity or Period of Limitations. All agreements and obligations of Brand Pharma contained herein shall continue for so long as Indemnitee shall be subject to, or involved in, any proceeding for which
indemnification is provided pursuant to this Agreement. Notwithstanding the foregoing, no legal action shall be brought and no cause of action shall be asserted by or on behalf of Brand Pharma or any Affiliate of Brand Pharma against Indemnitee,
Indemnitee’s spouse, heirs, executors, or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, or such longer period as may be required by the laws of Delaware under the
circumstances. Any claim or cause of action of Brand Pharma or its Affiliate shall be extinguished and deemed released unless asserted by the timely filing and notice of a legal action within such period; provided, however, that if any shorter
period of limitations is otherwise applicable to any such cause of action, the shorter period shall govern. 
 10. Contribution. To the
fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever (other than pursuant to the terms hereof), Brand Pharma, in lieu of indemnifying
Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an Indemnifiable Event
under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by Mallinckrodt plc and Brand Pharma, on one hand, and
Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of Mallinckrodt plc and Brand Pharma (and their respective directors, officers, employees and
agents), on one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s).

  
 - 10 -

 11. Amendment of this Agreement. No supplement, modification, or amendment of this Agreement shall
be binding unless executed in writing by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be binding unless in the form of a writing signed by the party against whom enforcement of the waiver is sought, and no
such waiver shall operate as a continuing waiver. Except as specifically provided herein, no failure to exercise or any delay in exercising any right or remedy hereunder shall constitute a waiver thereof.

12. Subrogation. In the event of payment under this Agreement, Brand Pharma shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable Brand Pharma effectively to bring suit to enforce
such rights.
 13. No Duplication of Payments. Brand Pharma shall not be liable under this Agreement to make any payment in connection
with any claim made by Indemnitee to the extent Indemnitee has otherwise received payment (under any insurance policy, Mallinckrodt plc’s Articles of Association, the separate deed of indemnification which Indemnitee has with Mallinckrodt plc,
the Brand Pharma Organizational Documents or otherwise) of the amounts otherwise indemnifiable hereunder. 
 14. Binding Effect. This
Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially
all of the business and/or assets of the Brand Pharma), assigns, spouses, heirs, and personal and legal representatives. Brand Pharma shall require and cause any successor thereof (whether direct or indirect by purchase, merger, consolidation, or
otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Brand Pharma, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the
same manner and to the same extent that Brand Pharma would be required to perform if no such succession had taken place. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while
serving in an indemnified capacity pertaining to an Indemnifiable Event even though he may have ceased to serve in such capacity at the time of any Proceeding or is deceased and shall inure to the benefit of the heirs, executors, administrators,
legatees and assigns of such a person.
 15. Severability. If any provision (or portion thereof) of this Agreement shall be held by a
court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of this Agreement containing any provision held to be invalid, void, or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent
manifested by the provision held invalid, void or unenforceable.
 16. Governing Law. This Agreement shall be governed by and construed
and enforced in accordance with the laws of Delaware applicable to contracts made and to be performed in such State without giving effects to its principles of conflicts of laws.

  
 - 11 -

 17. Notices. All notices, demands, and other communications required or permitted hereunder shall be
made in writing and shall be deem to have been duly given if delivered by hand, against receipt, or mailed, postage prepaid, certified or registered mail, return receipt requested, and address to Brand Pharma at: 

Mallinckrodt Brand Pharmaceuticals, Inc. 
 675 James S. McDonnell Blvd. 
 Hazelwood, MO 63042 

Attn: Secretary 

Facsimile: 314-654-5366 
 If to
Mallinckrodt plc, to: 
 Mallinckrodt plc 
 Damastown 
 Mulhuddart 

Dublin 15 

Ireland 
 Attn:
General Counsel 
 Facsimile: +353-1-820-8780 
 and 
 Mallinckrodt 

675 James S. McDonnell Blvd. 
 Hazelwood, MO 63042 
 Attn: General Counsel 

Facsimile: 314-654-5366 
 And to
Indemnitee at: 
 Notice of change of address shall be effective only when given in accordance with this Section. All notices complying with
this Section shall be deemed to have been received on the date of hand delivery or on the third business day after mailing. 
 18.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 - 12 -

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as
the day specified above. 
  

			
	 MALLINCKRODT BRAND PHARMACEUTICALS, INC.

 
  
  

 

	  

		
	 By:
	 	
	 Its:
	 	
	
	 INDEMNITEE

 
  
  

 

	  

	
	 Typed Name:

  
 - 13 -EX-10.6

 Exhibit 10.6 
 MALLINCKRODT PHARMACEUTICALS 
 SEVERANCE PLAN FOR U.S. OFFICERS AND
EXECUTIVES 
 Effective April 1, 2013 

 TABLE OF CONTENTS 

 

									
	 	 	 	    	 	  	Page	 
			
	 ARTICLE I
	    	 PURPOSE, INTENT AND TERM OF PLAN
	  	 	1	  
				
		 	 Section 1.01
	    	 Purpose and Intent of the Plan
	  	 	1	  
		 	 Section 1.02
	    	 Term of the Plan
	  	 	1	  
		 	 Section 1.03
	    	 Adoption of the Plan
	  	 	1	  
			
	 ARTICLE II
	    	 DEFINITIONS
	  	 	2	  
				
		 	 Section 2.01
	    	 Alternative Position
	  	 	2	  
		 	 Section 2.02
	    	 Annual Bonus
	  	 	2	  
		 	 Section 2.03
	    	 Base Salary
	  	 	2	  
		 	 Section 2.04
	    	 Board
	  	 	2	  
		 	 Section 2.05
	    	 Cause
	  	 	2	  
		 	 Section 2.06
	    	 Claim
	  	 	3	  
		 	 Section 2.07
	    	 Claimant
	  	 	3	  
		 	 Section 2.08
	    	 COBRA
	  	 	3	  
		 	 Section 2.09
	    	 Code
	  	 	3	  
		 	 Section 2.10
	    	 Committee
	  	 	3	  
		 	 Section 2.11
	    	 Company
	  	 	3	  
		 	 Section 2.12
	    	 Effective Date
	  	 	3	  
		 	 Section 2.13
	    	 Eligible Employee
	  	 	3	  
		 	 Section 2.14
	    	 Employee
	  	 	3	  
		 	 Section 2.15
	    	 Employer
	  	 	4	  
		 	 Section 2.16
	    	 ERISA
	  	 	4	  
		 	 Section 2.17
	    	 Exchange Act
	  	 	4	  
		 	 Section 2.18
	    	 Involuntary Termination
	  	 	4	  
		 	 Section 2.20
	    	 Key Employee
	  	 	4	  
		 	 Section 2.19
	    	 Named Appeals Fiduciary
	  	 	4	  
		 	 Section 2.21
	    	 Officer
	  	 	4	  
		 	 Section 2.22
	    	 Participant
	  	 	4	  
		 	 Section 2.23
	    	 Permanent Disability
	  	 	4	  
		 	 Section 2.24
	    	 Plan
	  	 	4	  
		 	 Section 2.25
	    	 Plan Administrator
	  	 	4	  
		 	 Section 2.26
	    	 Postponement Period
	  	 	5	  
		 	 Section 2.27
	    	 Release
	  	 	5	  
		 	 Section 2.28
	    	 Salary Continuation Benefits
	  	 	5	  
		 	 Section 2.29
	    	 Separation
	  	 	5	  
		 	 Section 2.30
	    	 Separation from Service
	  	 	5	  
		 	 Section 2.31
	    	 Separation from Service Date
	  	 	5	  
		 	 Section 2.32
	    	 Severance Benefits
	  	 	5	  
		 	 Section 2.33
	    	 Severance Period
	  	 	5	  
		 	 Section 2.34
	    	 Subsidiary
	  	 	6	  
		 	 Section 2.35
	    	 Termination Date
	  	 	6	  
		 	 Section 2.36
	    	 Voluntary Termination
	  	 	6	  

  
 -i-

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	    	 	  	Page	 
			
	 ARTICLE III
	    	 PARTICIPATION AND ELIGIBILITY FOR BENEFITS
	  	 	7	  
				
		 	 Section 3.01
	    	 Participation
	  	 	7	  
		 	 Section 3.02
	    	 Conditions
	  	 	7	  
			
	 ARTICLE IV
	    	 DETERMINATION OF SEVERANCE BENEFITS
	  	 	9	  
				
		 	 Section 4.01
	    	 Amount of Severance Benefits Upon Involuntary Termination
	  	 	9	  
		 	 Section 4.02
	    	 Voluntary Termination; Termination for Death or Permanent Disability
	  	 	12	  
		 	 Section 4.03
	    	 Termination for Cause
	  	 	12	  
		 	 Section 4.04
	    	 Reduction of Severance Benefits
	  	 	12	  
			
	 ARTICLE V
	    	 METHOD AND DURATION OF SEVERANCE BENEFIT PAYMENTS
	  	 	13	  
				
		 	 Section 5.01
	    	 Method of Payment
	  	 	13	  
		 	 Section 5.02
	    	 Other Arrangements
	  	 	13	  
		 	 Section 5.03
	    	 Code Section 409A
	  	 	13	  
		 	 Section 5.04
	    	 Termination of Eligibility for Benefits
	  	 	14	  
			
	 ARTICLE VI
	    	 THE PLAN ADMINISTRATOR
	  	 	15	  
				
		 	 Section 6.01
	    	 Authority and Duties
	  	 	15	  
		 	 Section 6.02
	    	 Compensation of the Plan Administrator
	  	 	15	  
		 	 Section 6.03
	    	 Records, Reporting and Disclosure
	  	 	15	  
			
	 ARTICLE VII
	    	 AMENDMENT, TERMINATION AND DURATION
	  	 	16	  
				
		 	 Section 7.01
	    	 Amendment, Suspension and Termination
	  	 	16	  
		 	 Section 7.02
	    	 Duration
	  	 	16	  
			
	 ARTICLE VIII
	    	 DUTIES OF THE COMPANY AND THE COMMITTEE
	  	 	17	  
				
		 	 Section 8.01
	    	 Records
	  	 	17	  
		 	 Section 8.02
	    	 Payment
	  	 	17	  
		 	 Section 8.03
	    	 Discretion
	  	 	17	  
			
	 ARTICLE IX
	    	 CLAIMS PROCEDURES
	  	 	18	  
				
		 	 Section 9.01
	    	 Claim
	  	 	18	  
		 	 Section 9.02
	    	 Initial Claim
	  	 	18	  
		 	 Section 9.03
	    	 Appeals of Denied Administrative Claims
	  	 	18	  
		 	 Section 9.04
	    	 Appointment of the Named Appeals Fiduciary
	  	 	19	  
		 	 Section 9.05
	    	 Arbitration; Expenses
	  	 	19	  
			
	 ARTICLE X
	    	 MISCELLANEOUS
	  	 	21	  
				
		 	 Section 10.01
	    	 Non-Alienation of Benefits
	  	 	21	  

  
 -ii-

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	    	 	  	Page	 
				
		 	 Section 10.02
	    	 Notices
	  	 	21	  
		 	 Section 10.03
	    	 Successors
	  	 	21	  
		 	 Section 10.04
	    	 Other Payments
	  	 	21	  
		 	 Section 10.05
	    	 No Mitigation
	  	 	21	  
		 	 Section 10.06
	    	 No Contract of Employment
	  	 	21	  
		 	 Section 10.07
	    	 Severability of Provisions
	  	 	21	  
		 	 Section 10.08
	    	 Heirs, Assigns, and Personal Representatives
	  	 	22	  
		 	 Section 10.09
	    	 Headings, Captions and Titles
	  	 	22	  
		 	 Section 10.10
	    	 Gender and Number
	  	 	22	  
		 	 Section 10.11
	    	 Unfunded Plan
	  	 	22	  
		 	 Section 10.12
	    	 Payments to Incompetent Persons
	  	 	22	  
		 	 Section 10.13
	    	 Lost Payees
	  	 	22	  
		 	 Section 10.14
	    	 Controlling Law
	  	 	22	  
				
		 		    	 Appendix
	  	 	A-1	  

  
 -iii-

 ARTICLE I 
 PURPOSE, INTENT AND TERM OF PLAN 
 Section 1.01 Purpose
and Intent of the Plan. The purpose of the Plan is to make available to Eligible Employees certain compensation and benefits in the event that such employee’s employment with the Company or, upon the Separation, a Subsidiary is
terminated under the circumstances, and subject to the conditions, described herein. The Plan is not intended to be an “employee pension benefit plan” or “pension plan” within the meaning of Section 3(2) of ERISA. Rather,
the Plan is intended to be a “welfare benefit plan” within the meaning of Section 3(1) of ERISA and to meet the requirements of a “severance pay plan” within the meaning of regulations published by the Secretary of Labor at
Title 29, Code of Federal Regulations, Section 2510.3-2(b). Accordingly, the Plan’s benefits are not deferred compensation, and no employee shall have a vested right to benefits provided by the Plan. The terms of the Plan are intended to,
and shall be interpreted so as to, comply in all respects with the provisions of Code Section 409A and the regulations and rulings promulgated thereunder. 
 Section 1.02 Term of the Plan. The Plan shall be effective as of the Effective Date and shall supersede any prior plan, program or policy under which the Company or, upon the
Separation, any Subsidiary provided severance benefits before the Effective Date. The Plan shall continue until terminated pursuant to the provisions set forth herein. 
 Section 1.03 Adoption of the Plan. In connection with the Separation, the Company adopted this Plan, effective April 1, 2013, for Eligible Employees of the Company and, effective
upon the Separation, Eligible Employees of any Subsidiary. Although the Separation is scheduled to occur on June 28, 2013, the Company adopted this Plan before the Separation as a result of the implementation of a separate payroll system for
its employees on April 1, 2013, and to ensure that a plan providing for severance benefits is in place for eligible employees of any United States Subsidiary in the Company’s controlled group after the Separation. 

 ARTICLE II 
 DEFINITIONS 
 Section 2.01 “Alternative
Position” shall mean a position with the Company or any Subsidiary that: 
 (a) is not more than 50 miles each way from
the location in which the Eligible Employee worked, and in the position such employee held, immediately before experiencing any job-related change (this mileage limitation shall apply only to jobs substantially performed in a single, fixed Company
or Subsidiary operated and maintained location and shall not apply to any job that requires extensive travel or that is performed offsite regularly); and 
 (b) provides the Eligible Employee with pay and benefits (not including perquisites or long-term incentive compensation) that are, in the aggregate, comparable to the pay and benefits of the position such
employee held immediately before experiencing any job-related change. 
 The Plan Administrator has the exclusive discretionary
authority to determine whether a position is an Alternative Position. 
 Section 2.02 “Annual
Bonus” shall mean the average of the actual bonuses paid to the respective Participant pursuant to The Covidien Annual Incentive Plan that are attributable to the three Company fiscal years that immediately precede the Participant’s
Separation from Service Date. 
 Section 2.03 “Base Salary” shall mean the Participant’s
annual base salary, excluding bonus and incentive compensation, in effect as of the Participant’s Termination Date. For Participants whose primary responsibilities on the applicable Termination Date involves the sale of products or managing
those whose primary responsibilities involve the sale of products and who receive compensation substantially based on sales of the products for which they are responsible (“Sales-Based Compensation”), Base Salary shall mean the
Participant’s annual base salary plus eighty five percent (85%) of the average Sales-Based Compensation actually paid to such Participant for the lesser of the preceding 24-month period or the number of whole months during which such
Participant received Sales-Based Compensation. Except as specifically described in this Section 2.02, Base Salary shall not include any compensation other than the Participant’s annual base salary. 

Section 2.04 “Board” shall mean the Board of Directors of Covidien plc; provided, however that subject to
and contingent upon the Separation and effective upon the Separation, “Board” shall mean the Board of Directors of Mallinckrodt plc. 
 Section 2.05 “Cause” shall mean an Employee’s (a) substantial failure or refusal to perform duties and responsibilities of his or her job as required by the Company
or Subsidiary, (b) violation of any fiduciary duty owed to the Company or Subsidiary, (c) conviction of a felony or misdemeanor, (d) dishonesty, (e) theft, (f) violation of Company or Subsidiary rules or policy, or
(g) other egregious conduct that has or could have a serious and detrimental impact on the Company or any Subsidiary or any of their employees. The Plan Administrator, in its sole and absolute discretion, shall determine whether Cause exists.

  
 -2-

 Section 2.06 “Claim” shall refer to a written claim for
Severance Benefits filed with the Plan Administrator pursuant to Article IX. 
 Section 2.07
“Claimant” shall mean an Eligible Employee who has experienced a termination of employment (or the beneficiary of such an Eligible Employee) and has asserted a right to Severance Benefits under the Plan. 

Section 2.08 “COBRA” shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and
the regulations promulgated thereunder. 
 Section 2.09 “Code” shall mean the Internal Revenue Code
of 1986, as amended, and the regulations promulgated thereunder. 
 Section 2.10 “Committee” shall
mean the Compensation and Human Resources Committee of the Board or such other committee appointed by the Board to assist the Company in making determinations required under the Plan in accordance with its terms. The Committee may delegate its
authority under the Plan to an individual or another committee. 
 Section 2.11 “Company” shall
mean Mallinckrodt Enterprises LLC, a Delaware limited liability company, and any entity that succeeds to the business or assumes the obligations of Mallinckrodt Enterprises LLC with respect to the Plan. 

Section 2.12 “Effective Date” shall mean April 1, 2013. 

Section 2.13 “Eligible Employee” shall mean an Employee who is an Officer or is classified in job grade D, E
or F and who is not covered under any other severance plan, program, benefit agreement or arrangement sponsored by the Company or any Subsidiary. “Eligible Employee” shall also mean an Employee who (i) is not considered to be an
Eligible Employee pursuant to the previous sentence; (ii) was an Eligible Employee under the Covidien Severance Plan for U.S. Officers and Executives as of December 31, 2011, based upon the terms of that plan as in effect on
December 31, 2011; and (iii) remains as an Employee in continuous employment from December 31, 2011 through the respective employment termination date. If there is any question as to whether an Employee is an Eligible Employee or the
level of severance benefits to which an Eligible Employee is entitled, the Plan Administrator shall make the determination in its sole discretion. 
 Section 2.14 “Employee” shall mean an individual who is a common law employee of the Company; provided, however, that subject to and contingent upon the Separation and
effective upon the Separation, “Employee” shall mean an individual considered by the Company or a Subsidiary to be a common law employee on the Company’s or Subsidiary’s United States payroll as evidenced by payroll records; and,
in either case, shall not include any person providing services to the Company or any Subsidiary through a temporary service or on a leased basis or who is hired by the Company or any Subsidiary as an independent contractor, consultant, or otherwise
as a person who is not an employee for purposes of withholding United States federal income or employment taxes, as evidenced by payroll records or a written agreement with the individual, regardless of any contrary governmental agency determination
or 

  
 -3-

 
judicial holding relating to such status or tax withholding. Notwithstanding the above, in the event that Code Section 409A applies to any payments made hereunder, subsection (d) of the
definition of “Subsidiary” shall apply solely with respect to any payments that are subject to Code Section 409A. 
 Section 2.15 “Employer” shall mean the Company or, if applicable, the Subsidiary that employs the Eligible Employee. 

Section 2.16 “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended, and the
regulations promulgated thereunder. 
 Section 2.17 “Exchange Act” shall mean the Securities
Exchange Act of 1934, as amended, and the regulations promulgated thereunder. 
 Section 2.18 “Involuntary
Termination” shall mean an Employer-initiated Separation from Service of a Participant for any reason other than Cause, Permanent Disability or death, as provided under and subject to the conditions of Article III. 

Section 2.19 “Key Employee” shall mean an Eligible Employee who is a “specified employee” under
Code Section 409A, as determined by the Company or its delegate. The determination of Key Employees, including the number and identity of persons considered specified employees and the identification date, shall be made by the Company or its
delegate in accordance with the provisions of Code Section 409A and the regulations promulgated thereunder. 

Section 2.20 “Named Appeals Fiduciary” shall mean the person or persons named as such in accordance with the
provisions of Section 9.04. 
 Section 2.21 “Officer” shall mean any individual who is an
officer, as such term is defined pursuant to Rule 16a-1(f) as promulgated under the Exchange Act, of Mallinckrodt plc. For purposes of this definition, Officer shall also mean any officer of any subsidiary of Mallinckrodt plc who performs policy
making functions, within the context of Rule 16a-1(f). 
 Section 2.22 “Participant” shall mean any
Eligible Employee who meets the requirements of Article III and thereby becomes eligible for Severance Benefits. 

Section 2.23 “Permanent Disability” shall mean that an Employee has a permanent and total incapacity from
engaging in any employment for the Employer for physical or mental reasons. A “Permanent Disability” shall be deemed to exist if the Employee is designated with an inactive employment status at the end of a disability or medical leave or
if the Employee meets the requirements for disability benefits under (a) the Employer’s long-term disability plan or (b) the Social Security law then in effect. 
 Section 2.24 “Plan” means the Mallinckrodt Pharmaceuticals Severance Plan for U.S. Officers and Executives as set forth herein, and as the same may from time to time be
amended. 
 Section 2.25 “Plan Administrator” shall mean the individual(s) appointed by the
Committee to administer the terms of the Plan as set forth herein and if no individual is appointed by the Committee to serve as the Plan Administrator, the Plan Administrator shall be 

  
 -4-

 
the Senior Vice President, Human Resources of Covidien plc; provided, however, that subject to and contingent upon the Separation and effective upon the Separation, if no individual is appointed
by the Committee to serve as the Plan Administrator, the Plan Administrator shall be the Senior Vice President, Human Resources of Mallinckrodt plc. Notwithstanding the preceding sentence, in the event the Plan Administrator is entitled to Severance
Benefits under the Plan, the Committee or its delegate (who shall not be the Plan Administrator) shall act as the Plan Administrator for purposes of administering the terms of the Plan with respect to the Plan Administrator. The Plan Administrator
may delegate all or any portion of its authority under the Plan to any other person(s). 
 Section 2.26
“Postponement Period” shall mean, for a Key Employee, the period of six (6) months after such Key Employee’s Separation from Service Date (or such other period as may be required by Code Section 409A). 

Section 2.27 “Release” shall mean a written agreement, in substance and form suitable to the Company, by
which a Participant agrees to waive and release the Company and, if applicable, the Employer from all legal claims the Participant may have against the Company and, if applicable, the Employer in exchange for Severance Benefits. The Release shall
include the Participant’s written agreement to confidentiality, non-solicitation, non-disparagement and, where applicable, non-competition provisions. To be effective, the Release must be signed and returned to the Company within the timeframe
set forth in the Release, but no later than sixty (60) days following the Participant’s Separation from Service Date, and it may not be revoked during any applicable revocation period that may be permitted by the Release or applicable law.
Releases are not required to be identical amongst Participants. 
 Section 2.28 “Salary Continuation
Benefits” shall mean the salary continuation payments described in Section 4.01(b) and the bonus payments described in Section 4.01(c)(ii). 
 Section 2.29 “Separation” shall mean the separation of Covidien plc’s Pharmaceuticals business (a/k/a Mallinckrodt Pharmaceuticals) from Covidien plc in a transaction set
forth in a Form 10 initially filed with the U.S. Securities and Exchange Commission on February 1, 2013, whereby the public shareholders of Covidien plc are issued a stock dividend of Mallinckrodt plc ordinary shares and, as a result of such
transaction and immediately upon the consummation of such transaction, the Company will no longer be a member of the Covidien plc controlled group of corporations. 
 Section 2.30 “Separation from Service” shall mean “separation from service” within the meaning of Code Section 409A(a)(2)(A)(i) and the applicable regulations
and rulings promulgated thereunder. 
 Section 2.31 “Separation from Service Date” shall mean, with
respect to a Participant, the date on which such Participant experiences a Separation from Service. 
 Section 2.32
“Severance Benefits” shall mean the Salary Continuation Benefits and other benefits that a Participant is eligible to receive pursuant to Article IV of the Plan. 

Section 2.33 “Severance Period” shall mean the period during which a Participant is receiving Severance
Benefits under this Plan, as set forth in the Appendix. 

  
 -5-

 Section 2.34 “Subsidiary” shall mean (a) a subsidiary
company (wherever incorporated) of Mallinckrodt plc, as defined by Section 155 of the Companies Act 1963 of Ireland; (b) any separately organized business unit, whether or not incorporated, of Mallinckrodt plc; (c) any employer that
is required to be aggregated with the Company pursuant to Code Section 414 and the regulations promulgated thereunder; and (d) any service recipient or employer that is within a controlled group of corporations as defined in Code Sections
1563(a)(1), (2) and (3) where the phrase “at least 50%” is substituted in each place “at least 80%” appears and any service recipient or employer within trades or businesses under common control as defined in Code
Section 414(c) and Treas. Reg. Section 1.414(c)-2 where the phrase “at least 50%” is substituted in each place “at least 80%” appears, provided, however, that when the relevant determination is to be based upon
legitimate business criteria (as described in Treas. Reg. Sections 1.409A-1(b)(5)(iii)(E) and 1.409A-1(h)(3)), the phrase “at least 20%” shall be substituted in each place “at least 80%” appears as described above with respect to
both a controlled group of corporations and trades or business under common control. 
 Section 2.35
“Termination Date” shall mean the date on which the active employment of the Participant by the Employer ceases by reason of an Involuntary Termination. 
 Section 2.36 “Voluntary Termination” shall mean any Separation from Service due to a termination of employment that is not initiated by the Employer. 

  
 -6-

 ARTICLE III 
 PARTICIPATION AND ELIGIBILITY FOR BENEFITS 
 Section 3.01
Participation. Each Eligible Employee in the Plan who experiences an Involuntary Termination and who satisfies all of the conditions of Section 3.02 shall be eligible to receive Severance Benefits. An Eligible Employee shall not be
eligible to receive any other benefits from the Company or any Subsidiary on account of an Involuntary Termination, unless otherwise provided in the Plan. 
 Section 3.02 Conditions. 
 (a) Eligibility for any Severance
Benefits is expressly conditioned upon the Eligible Employee’s execution of the Release within the timeframe set forth in the Release, but no later than sixty (60) days following such employee’s Separation from Service Date, including
the Eligible Employee’s written acceptance of, and written agreement to comply with, the confidentiality, non-solicitation, non-disparagement and non-competition provisions set forth in the Release. To the extent permitted in Section 4.04,
eligibility for any Severance Benefits also is expressly conditioned upon the Eligible Employee’s written agreement that authorizes the deduction of amounts owed to the Employer prior to the payment of any Severance Benefits (or in accordance
with any other schedule as the Plan Administrator may, in its sole discretion, determine to be appropriate). If the Plan Administrator determines, in its sole discretion, that the Participant has not fully complied with any of the terms of the
Release, the Plan Administrator may, to the extent consistent with the terms of any Release, deny Severance Benefits not yet in pay status or discontinue the payment of the Participant’s Severance Benefits and may require the Participant, by
providing written notice of such repayment obligation to the Participant, to repay any portion of the Severance Benefits already received under the Plan. If the Plan Administrator notifies a Participant that repayment of all or any portion of the
Severance Benefits received under the Plan is required, such amounts shall be repaid within thirty (30) calendar days after the date the written notice is sent. Any remedy under this Section 3.02(a) shall be in addition to, and not in
place of, any other remedy, including injunctive relief, that the Company may have. 
 (b) An Eligible Employee will not be
eligible to receive Severance Benefits under any of the following circumstances: 
 (i) A Voluntary Termination
by the Eligible Employee (unless the selection criteria for an Employer-established exit program permit the Eligible Employee to terminate employment voluntarily in exchange for participation in such program, the Employer provides the Eligible
Employee with written acceptance of his or her request to participate in that program and the Eligible Employee satisfies all relevant conditions for participation in such program); 

(ii) The Eligible Employee resigns during any time period when the Employer otherwise would retain the Eligible
Employee’s services; 
 (iii) The Eligible Employee’s employment is terminated for Cause; 

  
 -7-

 (iv) The Eligible Employee’s employment terminates due to the Eligible
Employee’s death or Permanent Disability; 
 (v) The Eligible Employee does not return to work within the
time frame required following an approved leave of absence; 
 (vi) The Eligible Employee does not satisfy the
conditions for Severance Benefits set forth in Section 3.02(a); 
 (vii) The Eligible Employee continues in
employment with the Employer in any position or has the opportunity to continue in employment in the same or in an Alternative Position with the Company or any Subsidiary; 

(viii) The Eligible Employee’s employment with the Employer terminates as a result of a sale of stock or assets of
the Employer, merger, consolidation, joint venture or a sale or outsourcing of a business unit or function, or other transaction, and the Eligible Employee accepts employment, or has the opportunity to continue employment (without regard to whether
the offer of employment is for an Alternative Position), with the purchaser, joint venture or other acquiring or outsourcing entity or a related entity of either the Employer or the acquiring entity. The payment of Severance Benefits in the
circumstances described in this subsection 3.02(b)(viii) would result in a windfall to the Eligible Employee, which is not the intention of the Plan; or 
 (ix) The Eligible Employee fails to timely execute, or executes but timely revokes acceptance of, the Release. 
 (c) The Plan Administrator has the sole discretion to determine an Eligible Employee’s eligibility to receive Severance Benefits. 

(d) An Eligible Employee who returns from approved military leave and meets the following three conditions will be eligible for Severance
Benefits: (i) the Eligible Employee is eligible for reemployment under the provisions of the Uniformed Services Employment and Reemployment Rights Act; (ii) the Eligible Employee’s pre-military leave job is eliminated; and
(iii) the Employer’s circumstances are changed so as to make reemployment in another position impossible or unreasonable, or re-employment would create an undue hardship for the Employer. The Severance Benefits provided to a Participant
returning from military leave will be calculated as if the Participant had remained continuously employed from the date on which military leave commenced. An Eligible Employee who returns from approved military leave also must satisfy any other
relevant conditions for payment set forth in this Article III, including execution of the Release. 

  
 -8-

 ARTICLE IV 
 DETERMINATION OF SEVERANCE BENEFITS 
 Section 4.01 Amount
of Severance Benefits Upon Involuntary Termination. The Severance Benefits to be provided to a Participant shall be as follows: 
 (a) Notice Pay. Each Eligible Employee who is eligible for Severance Benefits shall receive Notice Pay (or pay in lieu of notice, as applicable) without regard to whether the Eligible Employee
receives Severance Benefits. Unless otherwise provided herein, Notice Pay means the continued payment of a pro-rata portion of the Eligible Employee’s annual base salary (excluding bonus and incentive compensation and Sales-Based Compensation)
during the thirty (30) calendar-day period which begins the day immediately after the date the Employer informs the Eligible Employee of his or her Involuntary Termination (“Notice Period”). If the Employer determines that an Eligible
Employee’s Termination Date shall be before the expiration of such employee’s Notice Period, the Company shall provide to the Eligible Employee pay in lieu of notice, which shall equal the pro-rata portion of the Eligible Employee’s
annual base salary (excluding bonus and incentive compensation and Sales-Based Compensation) applicable to the period beginning on the day after the employee’s Termination Date and ending on the last day of the Notice Period. Pay in lieu of
notice shall be paid to the Eligible Employee in a single lump sum payment (net of deductions and tax withholdings, as applicable) no later than the second regular Employer pay period that occurs after the Eligible Employee’s Termination Date.
Notice Pay (or pay in lieu of notice, as applicable) shall be in addition to, and shall not be offset against, any Severance Benefits an Eligible Employee may receive pursuant to the Plan. An Eligible Employee who fails to timely execute, or who
executes but timely revokes acceptance of, the Release shall not be entitled to Severance Benefits hereunder and shall only be eligible to receive Notice Pay (or pay in lieu of notice, as applicable). Unless otherwise permitted by the applicable
plan document or as specifically required by applicable law, an Eligible Employee with a Termination Date that occurs before expiration of the applicable Notice Period shall not be eligible to apply for short- or long-term disability or
workers’ compensation benefits in connection with any injury that occurs or disability that arises after such employee’s Termination Date. 
 (b) Salary Continuation. Salary continuation payments shall be provided during the Severance Period applicable to the Participant, as set forth in the Salary Continuation Schedule in the Appendix.
During the Severance Period, the Participant shall receive continued payments of a pro-rata portion of Base Salary (net of deductions and tax withholdings, as applicable) in equal installments over the Severance Period, per normal payroll cycles and
in normal payroll amounts for such cycle. Except as otherwise provided herein, salary continuation payments shall commence no earlier than the end of the applicable revocation period and shall be paid in accordance with Article V. 

(c) Bonus. 
 (i) Participants may be eligible for a cash payment equal to such Participant’s pro-rated annual bonus for the year in which the Participant’s Separation from Service Date occurs, subject to the
discretion of the Company and to the extent provided in the applicable plan. 

  
 -9-

 (ii) Participants shall also receive a bonus payment during the applicable Severance Period
that is equal to the amount set forth in the Bonus Payment Schedule in the Appendix. The bonus payment shall be paid in cash to the Participant in equal installments over the applicable Severance Period (e.g., 12 months, 18 months or 24
months), per normal payroll cycles. Bonus payments made over the applicable Severance Period shall be paid at the same time as the salary continuation payments described in Section 4.01(b) and in accordance with Article V. 

(d) Medical, Dental and Health Care Reimbursement Account Benefits. The Participant (and his/her spouse, domestic partner or
child(ren), as applicable) shall be eligible for continued coverage under the Company’s medical and dental plans as required by and pursuant to COBRA. The Company shall provide COBRA coverage only if such coverage is timely elected by the
Participant or other qualified beneficiary (as defined by COBRA). If the Participant timely elects COBRA coverage, subject to the other provisions in this Section 4.01(d), during the Severance Period, the Participant will be responsible for
paying the employee portion of the applicable premium under the respective plan(s) at the same rate and at the same time as such employee contributions are paid by similarly-situated then-active Company employees. If the Severance Period is less
than the applicable COBRA coverage period then, effective for the first premium payment due after the Severance Period expires, the Participant will be required to pay the entire premium for COBRA coverage and shall be responsible for paying such
premium during the remainder of the applicable COBRA coverage period. If the Severance Period exceeds eighteen (18) months after the Participant’s Separation from Service Date, then (a) effective for any premium payments for COBRA
coverage that are due after eighteen (18) months after the Participant’s Separation from Service Date, the Participant will be required to pay the entire premium for such COBRA coverage and shall be responsible for paying such premium
during the remainder of the applicable COBRA period and (b) the Company shall pay to the Participant, within sixty (60) days after such eighteen (18) month period expires, a single lump-sum cash payment in an amount equal to the
employer portion of the applicable premium in effect for the Participant, based on the type of coverage provided to the Participant at such time, for the last month of such eighteen (18) month period times the number of full months that the
Severance Period exceeds such eighteen (18) month period. COBRA coverage will cease upon the expiration of the maximum period required under COBRA or at such earlier time if the Participant does not pay the required premium within the
applicable time period, if the Participant terminates COBRA coverage, or if an event occurs that, pursuant to COBRA, permits the earlier termination of COBRA coverage. 
 (e) Equity Awards. Except as otherwise provided in Section 4.01(e)(i) through (iii) below, all equity awards over Covidien plc ordinary shares (or, after the Separation, Mallinckrodt plc
ordinary shares) that are held by the Participant as of his or her Separation from Service Date shall be treated in accordance with the terms and conditions of the applicable plan and award agreement under which such awards were granted. 

(i) Stock Options. All stock options held by the Participant as of such Participant’s Separation from Service Date which
would have vested and become exercisable during the twelve (12) month period occurring immediately after the Participant’s Separation 

  
 -10-

 
from Service Date shall accelerate and become immediately vested and exercisable on such Participant’s Separation from Service Date, unless the applicable option agreement provides for more
favorable vesting treatment. All outstanding stock options held by the Participant that are vested and exercisable as of the Participant’s Separation from Service Date (including options that vest and become exercisable pursuant to the
provisions of this Section 4.01(e)(i) or Section 4.01(e)(iii) below in the case of Normal Retirement) shall be exercisable for the greater of (A) the period set forth in applicable option agreement, or (B) twelve (12) months
after the Participant’s Separation from Service Date. In no event, however, shall an option be exercisable beyond its original expiration date. If the Participant dies, the terms and conditions of the applicable option agreement shall govern.

 (ii) Restricted Stock, Restricted Units and Performance Units. All unvested restricted stock and restricted units
held by a Participant as of such Participant’s Separation from Service Date shall be forfeited as of the Participant’s Separation from Service Date. All performance units held by a Participant as of such Participant’s Separation from
Service Date shall be forfeited as of the Participant’s Separation from Service Date. 
 (iii) Retirement and Normal
Retirement Eligible Participants. Notwithstanding the provisions of Section 4.01(e)(i) and (ii), if a Participant who signs a Release and begins receiving Severance Benefits hereunder would satisfy the requirements for Retirement or Normal
Retirement (as such terms are defined in the applicable award agreement) set forth in a non-qualified stock option, restricted unit or performance unit award agreement over Covidien plc ordinary shares (or, after the Separation, Mallinckrodt plc
ordinary shares) at any time during the Participant’s Severance Period solely by reason of attaining the requisite age set forth in the applicable award agreement during such Severance Period, then all such non-qualified stock option,
restricted unit and performance unit awards shall vest in accordance with the terms and conditions of the applicable award agreement by treating such Participant as if such Participant had satisfied the age requirement for Retirement or Normal
Retirement, as applicable, under the applicable award agreement on the Participant’s Separation from Service Date; provided, however that, solely with respect to non-qualified stock options, if Section 4.01(e)(i) provides more favorable
treatment than this Section 4.01(e)(iii) (as would be the case if Retirement treatment applied), the more favorable provision shall apply. If the Participant dies, the terms and conditions of the applicable award agreement shall govern.

 (f) Outplacement Services. The Company may, in its sole and absolute discretion, pay the cost of outplacement services
for the Participant at the outplacement agency that the Company regularly uses for such purpose; provided, however, that the period of outplacement shall not exceed twelve (12) months after the Participant’s Separation from Service
Date or, if earlier, the date of the Participant’s death. 

  
 -11-

 Section 4.02 Voluntary Termination; Termination for Death or Permanent
Disability. If the Eligible Employee’s employment terminates on account of (a) the Eligible Employee’s Voluntary Termination, (b) death or (c) Permanent Disability, then the Eligible Employee shall not be entitled to
receive Severance Benefits under this Plan and shall be entitled only to those benefits (if any) as may be available under the Company’s benefit plans and policies in effect at the time of such termination of employment. 

Section 4.03 Termination for Cause. If any Eligible Employee’s employment terminates on account of termination by
the Employer for Cause, the Eligible Employee shall not be entitled to receive Severance Benefits under this Plan and shall be entitled only to those benefits that are required to be provided to the Eligible Employee by applicable law.
Notwithstanding any other provision of the Plan to the contrary, if the Plan Administrator in its sole discretion determines, at any point during the Severance Period, that a Participant engaged in conduct that constitutes Cause, any Severance
Benefits payable to the Participant shall cease immediately, and the Participant shall be required to return to the Company any Severance Benefits that were provided to the Participant before such determination. The Company may withhold providing
Severance Benefits pending resolution of an inquiry that could lead to a finding that an Eligible Employee engaged in conduct that constitutes Cause. Any such Severance Benefit that is withheld and subsequently is determined to be due shall be
provided to the Participant within ninety (90) days after the date of the final and binding resolution. 

Section 4.04 Reduction of Severance Benefits. With respect to amounts paid under the Plan that are not subject to Code
Section 409A and the regulations promulgated thereunder, the Plan Administrator reserves the right to make deductions in accordance with applicable law for any monies owed to the Employer by the Eligible Employee or for the value of any
Employer property that the Eligible Employee improperly retains and fails to return to the Employer. With respect to amounts paid under the Plan that are subject to Code Section 409A and the regulations promulgated thereunder, the Plan
Administrator reserves the right to make deductions in accordance with applicable law for any monies owed to the Employer by the Eligible Employee or the value of Employer property that the Eligible Employee has retained; provided, however, that
such deductions cannot exceed $5,000 in the aggregate in any Employer fiscal year. 

  
 -12-

 ARTICLE V 
 METHOD AND DURATION OF SEVERANCE BENEFIT PAYMENTS 

Section 5.01 Method of Payment. Subject to Section 5.03, the Severance Benefits to which a Participant is
entitled, as determined pursuant to Section 4.01, shall be paid by the Company in accordance with normal payroll practices over the Severance Period; provided, however, that the pro rated annual bonus payable to the Participant pursuant to
Section 4.01(c)(i) shall be paid at such time and in such manner as set forth in the applicable annual incentive bonus plan and that COBRA coverage under Section 4.01(d) shall be provided or paid in accordance with the provisions of that
subsection. In no event will interest be credited on the unpaid balance for which a Participant may become eligible. Payment shall be mailed to the last address provided by the Participant to the Company or made by such other reasonable method as
determined by the Plan Administrator. All payments of Severance Benefits are subject to applicable federal, state and local taxes and withholdings. In the event of a Participant’s death prior to the completion of all payments to which a
Participant is entitled, the remaining payments shall be paid to the Participant’s estate in a single, lump-sum payment within sixty (60) days following the date the Company receives notice of the Participant’s death. 

Section 5.02 Other Arrangements. The Severance Benefits under this Plan are not additive or cumulative to severance or
termination benefits that a Participant might also be entitled to receive under the terms of a written employment agreement, a severance agreement or any other arrangement with the Employer including, but not limited to, the Covidien Severance Plan
for U.S. Officers and Executives. Notwithstanding any other provision of this Plan, any Eligible Employee who is a party to an employment agreement with the Company pursuant to which such Eligible Employee is entitled to severance benefits shall be
ineligible to participate in the Plan. With respect to those Eligible Employees who are eligible for severance or other payments resulting from a termination of employment under a plan or arrangement other than this Plan, as a condition of receiving
Severance Benefits under this Plan, the Plan Administrator, in its sole discretion, must determine that the Eligible Employee is eligible under this Plan and the Eligible Employee must expressly agree that this Plan supersedes all prior agreements
including, but not limited to, the Covidien Severance Plan for U.S. Officers and Executives, and sets forth the full and complete benefits to which the Eligible Employee is entitled upon an Involuntary Termination. 

Section 5.03 Code Section 409A 
 (a) Notwithstanding any other provision of the Plan to the contrary, if required by Code Section 409A, no Salary Continuation Benefits shall be paid to a Participant who is a Key Employee during the
Postponement Period. If the previous sentence applies, then the payment of Salary Continuation Benefits shall commence after expiration of the applicable Postponement Period and any amounts that would have been paid during the Postponement Period
but for the previous sentence shall be paid in a single, lump-sum within thirty (30) days after the end of such Postponement Period. If the Participant dies during the Postponement Period, however, amounts withheld pursuant to this
Section 5.03(a) shall be paid to the Participant’s estate no later than the earlier of sixty (60) days after the date the Company receives notice of the Participant’s death or thirty (30) days after the end of the
Postponement Period. 

  
 -13-

 (b) This Plan is intended to provide certain benefits that meet the requirements of the
“short-term deferral” exception, the “separation pay” exception and other exceptions under Code Section 409A and the regulations promulgated thereunder. Notwithstanding any other provision of the Plan to the contrary, if
required by Code Section 409A, payments may be made under this Plan only upon an event and in a manner permitted by Code Section 409A. For purposes of Code Section 409A, each individual payment that constitutes part of the Salary
Continuation Benefits shall be treated as a separate payment from any other such payment. All reimbursements and in-kind benefits provided under the Plan shall be made or provided in accordance with the requirements of Code Section 409A
including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the period of time specified in the Plan, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during
a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made no later than the last day of the calendar year
following the year in which the expense is incurred, and (iv) the right to reimbursement, or in-kind benefits is not subject to liquidation or exchange for another benefit. In no event may a Participant designate the year of payment for any
amounts payable under the Plan. 
 Section 5.04 Termination of Eligibility for Benefits. 

(a) All Eligible Employees shall cease to be eligible to participate in the Plan, and all Severance Benefits payable to a Participant
shall cease upon the occurrence of the earlier of: 
 (i) Subject to Article VII, termination or modification of the Plan; or

 (ii) Completion of the provision of Severance Benefits to the Participant. 

(b) Notwithstanding any other provision of the Plan to the contrary, the Company shall have the right to cease all Severance Benefits
(except as otherwise required by law) and to recover any payments previously made to the Participant if: 
 (i)
the Participant, at any time, breaches the Participant’s undertakings under the terms of the Plan; 
 (ii)
the Participant fails to comply with the terms of the Release the Participant executed to obtain Severance Benefits or fails to comply with any confidentiality, non-solicitation, non-disparagement or non-competition covenant applicable to the
Participant; or 
 (iii) the Company becomes aware of any circumstances that would have justified termination of
the Participant’s employment for Cause. 

  
 -14-

 ARTICLE VI 
 THE PLAN ADMINISTRATOR 
 Section 6.01 Authority and
Duties. It shall be the duty of the Plan Administrator, on the basis of information supplied to it by the Employer, to administer the Plan. The Plan Administrator shall have the full and absolute power, authority and discretion to construe,
interpret and administer the Plan, to make factual determinations, to correct deficiencies therein and to supply omissions. All decisions, actions and interpretations of the Plan Administrator shall be final, binding and conclusive upon all parties,
subject only to the Claims Procedure as defined in Article IX, and may not be overturned unless found by a court to be arbitrary and capricious. The Plan Administrator may adopt such rules and regulations and may make such decisions as it deems
necessary or desirable for the proper administration of the Plan. 
 Section 6.02 Compensation of the Plan
Administrator. The Plan Administrator shall receive no compensation for services as such. However, all reasonable expenses of the Plan Administrator shall be paid or reimbursed by the Company upon proper documentation. The Plan Administrator
shall be indemnified by the Company against personal liability for actions taken in good faith in the discharge of the Plan Administrator’s duties pursuant to the policy entitled “Indemnification of Directors, Officers, and Employees Who
Serve As Fiduciaries or Representatives,” as the same may from time to time be amended, or pursuant to such other policy as may apply to the Plan Administrator. 
 Section 6.03 Records, Reporting and Disclosure. The Plan Administrator or its delegate shall keep a copy of all records relating to the payment of Severance Benefits to Participants and
former Participants and all other records necessary for the proper operation of the Plan. All Plan records shall be made available to the Committee, the Company and to each Participant for examination during business hours, except that a Participant
shall be entitled to examine only such records as pertain exclusively to the examining Participant and to the Plan. The Plan Administrator shall prepare and shall file as required by law or regulation all reports, forms, documents and other items
required by ERISA, the Code and every other relevant statute, each as amended, and all regulations promulgated thereunder (except that the Company, as payor of the Severance Benefits, shall prepare and distribute to the proper recipients all forms
relating to withholding of income or wage taxes, Social Security taxes and other amounts that may be similarly reportable). 

  
 -15-

 ARTICLE VII 
 AMENDMENT, TERMINATION AND DURATION 
 Section 7.01
Amendment, Suspension and Termination. Except as otherwise provided in this Section 7.01, the Board, by action of the Compensation and Human Resources Committee, shall have the right, at any time and from time to time, to amend,
suspend or terminate the Plan in whole or in part, for any reason or without reason, and without either the consent of or the prior notification to any Participant, by a formal written action. No such amendment shall give the Company the right to
recover any amount paid to a Participant prior to the date of such amendment or to cause the cessation of Severance Benefits already approved for a Participant who has executed the Release (and has not revoked his or her agreement to the Release).
Any amendment or termination of the Plan must comply with all applicable legal requirements including, without limitation, compliance with Code Section 409A and the regulations and rulings promulgated thereunder, securities, tax, or other laws,
rules, regulations or regulatory interpretation thereof, applicable to the Plan. 
 Section 7.02 Duration.
The Plan shall continue in full force and effect until its termination; provided, however, that after the Plan’s termination, if Participants who experienced an Involuntary Termination before the Plan terminates are receiving Severance
Benefits, the Plan shall remain in effect until all of the obligations of the Company are satisfied with respect to such Participants. 

  
 -16-

 ARTICLE VIII 
 DUTIES OF THE COMPANY AND THE COMMITTEE 
 Section 8.01
Records. The Company or Subsidiary, as applicable, shall supply to the Committee all records and information necessary to the performance of the Committee’s duties. 

Section 8.02 Payment. The provision of Severance Benefits to Participants shall be made from the Company’s
general assets, in accordance with the terms of the Plan. 
 Section 8.03 Discretion. Any decisions, actions
or interpretations to be made under the Plan by the Board, the Committee or the Plan Administrator, acting on behalf of either, shall be made in each of their respective sole discretion, not in any fiduciary capacity and need not be uniformly
applied to similarly situated individuals and such decisions, actions or interpretations shall be final, binding and conclusive upon all parties. As a condition of participating in the Plan, the Eligible Employee acknowledges that all decisions and
determinations of the Board, the Committee and the Plan Administrator shall be final and binding on the Eligible Employee, the Eligible Employee’s beneficiaries and any other person having or claiming an interest under the Plan on behalf of an
Eligible Employee. 

  
 -17-

 ARTICLE IX 
 CLAIMS PROCEDURES 
 Section 9.01 Claim. If a
person asserts a right to, but does not receive, a benefit under the Plan, such person or such person’s authorized representative shall, within thirty (30) days following the person’s Termination Date, file with the Plan Administrator
a written claim for such benefit. Claims not timely filed shall be barred. A Participant under this Plan may contest only the administration of the Severance Benefits awarded. To request such review, a Participant shall complete and file with the
Plan Administrator a written request for review in the manner specified by the Plan Administrator. Except as set forth herein, no appeal is permissible as to a person’s eligibility for or amount of the Severance Benefits, which decisions are
made solely within the discretion of the Plan Administrator. No person may bring an action for any alleged wrongful denial of Plan benefits in a court of law unless the claims procedures described in this Article IX are exhausted and a final
determination is made by the Plan Administrator and/or the Named Appeals Fiduciary. If an Eligible Employee or Participant or other interested person challenges a decision by the Plan Administrator and/or Named Appeals Fiduciary, a review by the
court of law will be limited to the facts, evidence and issues presented to the Plan Administrator during the claims procedures set forth in this Article IX. Facts and evidence that become known to the terminated Eligible Employee or Participant or
other interested person after such person has exhausted the claims procedures set forth in this Article IX must be brought to the attention of the Plan Administrator for reconsideration by the Plan Administrator. Any issue that is not raised with
the Plan Administrator and/or Named Appeals Fiduciary will be deemed waived. 
 Section 9.02 Initial Claim.
Before the date on which payment of Severance Benefits commences, each Claim must be supported by such information as the Plan Administrator deems relevant and appropriate. In the event that any Claim relating to the administration of Severance
Benefits is denied in whole or in part, the Claimant whose claim has been so denied shall be notified of such denial in writing by the Plan Administrator within ninety (90) days after the receipt of the claim for benefits. This period may be
extended an additional ninety (90) days if the Plan Administrator determines such extension is necessary and the Plan Administrator provides notice of extension to the Claimant before the end of the initial ninety (90) day period. The
notice advising of the denial shall: (a) specify the reason or reasons for denial; (b) refer specifically to the Plan provisions on which the determination was based; (c) describe any additional material or information necessary for
the Claimant to perfect the claim (explaining why such material or information is needed); and (d) describe the Plan’s review procedures and the time limits applicable to such procedures, including a statement of the Claimant’s right
to bring a civil action under ERISA Section 502(a) following an adverse benefit determination on review. If it is determined that payment is to be made, any such payment shall be made within ninety (90) days after the date by which
notification is required. 
 Section 9.03 Appeals of Denied Administrative Claims. All appeals shall be made
by the following procedure: 
 (a) A Claimant whose Claim has been denied shall file with the Plan Administrator a notice of
appeal of the denial. Such notice shall be filed within sixty (60)

  
 -18-

 
calendar days after notification by the Plan Administrator of the denial of a Claim, shall be made in writing, and shall set forth all of the facts upon which the appeal is based. Appeals not
timely filed shall be barred. 
 (b) The Named Appeals Fiduciary shall consider the merits of the Claimant’s written
presentations, the merits of any facts or evidence in support of the denial of benefits and such other facts and circumstances as the Named Appeals Fiduciary shall deem relevant. 

(c) The Named Appeals Fiduciary shall render a determination upon the appealed claim, and the determination shall be accompanied by a
written statement as to the reasons therefore. The determination shall be provided to the Claimant within sixty (60) days after the Plan Administrator receives the Claimant’s request for review, unless the Named Appeals Fiduciary
determines that special circumstances require an extension of time for processing the claim. In such case, the Named Appeals Fiduciary shall notify the Claimant of the need for an extension of time to render its decision prior to the end of the
initial sixty (60) day period, and the Named Appeals Fiduciary shall have an additional sixty (60) day period to make its determination. The determination so rendered shall be binding upon all parties. If the determination is adverse to
the Claimant, the notice shall: (a) provide the reason or reasons for denial; (b) make specific reference to the Plan provision’s on which the determination was based; (c) include a statement that the Claimant is entitled to
receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to a the Claimant’s claim for benefits; and (d) state that the Claimant has the right to bring an action
under ERISA Section 502(a). If the final determination is that payment shall be made, then any such payment shall be made within ninety (90) days after the date by which notification of the final determination is required. 

Section 9.04 Appointment of the Named Appeals Fiduciary. The Named Appeals Fiduciary shall be the person or persons
named as such by the Committee, or, if no such person or persons be named, then the Committee shall be the Named Appeals Fiduciary. Named Appeals Fiduciaries, named as such by the Committee, may at any time be removed by the Committee. All such
removals may be with or without cause and shall be effective on the date stated in the notice of removal. The Named Appeals Fiduciary shall be a “Named Fiduciary” within the meaning of ERISA, and unless appointed to other fiduciary
responsibilities, shall have no authority, responsibility or liability with respect to any matter other than the proper discharge of the functions of the Named Appeals Fiduciary as set forth herein. 

Section 9.05 Arbitration; Expenses. In the event of any dispute under the provisions of this Plan, other than a
dispute in which the primary relief sought is an equitable remedy such as an injunction, the parties shall have the dispute, controversy or claim settled by arbitration in St. Louis, Missouri (or such other location as may be mutually agreed upon by
the Company and the Participant) in accordance with the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association then in effect, before a single arbitrator. Any award entered by the arbitrator shall be final,
binding and non-appealable, and judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision shall be specifically enforceable. The arbitrator shall have no
authority to modify any provision of this Plan or to award a remedy for a dispute involving this Plan other than a benefit specifically provided under or by virtue of the Plan. If the Participant substantially prevails on any material issue, which
is the subject of such arbitration or lawsuit, the Company 

  
 -19-

 
shall be responsible for all of the fees of the American Arbitration Association and the arbitrator and any reasonably incurred expenses relating to the conduct of the arbitration (including the
Company’s and Participant’s reasonable attorneys’ fees and expenses); in this event, any such fees and expenses are limited to those typically incurred in the usual course of arbitration proceedings and shall not be negotiable or
determinable by the Participant, and payment to the Participant of such amounts shall occur within ninety (90) days after the date of entry of judgment (entered in accordance with applicable law in any court of competent jurisdiction) of the
final, binding and non-appealable arbitration settlement. Otherwise, each party shall be responsible for its own expenses relating to the conduct of the arbitration (including reasonable attorneys’ fees and expenses) and shall share the fees of
the American Arbitration Association. 

  
 -20-

 ARTICLE X 
 MISCELLANEOUS 
 Section 10.01 Non-Alienation of
Benefits. None of the payments, benefits or rights of any Participant shall be subject to any claim of any creditor of any Participant, and, in particular, to the fullest extent permitted by law, all such payments, benefits and rights shall
be free from attachment, garnishment (if permitted under applicable law), trustee’s process or any other legal or equitable process available to any creditor of such Participant. No Participant shall have the right to alienate, anticipate,
commute, plead, encumber or assign any of the benefits or payments that he may expect to receive, contingently or otherwise, under this Plan. 
 Section 10.02 Notices. All notices and other communications required hereunder shall be in writing and shall be delivered personally or mailed by registered or certified mail, return
receipt requested, or by overnight express courier service. In the case of the Participant, mailed notices shall be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the
Company, mailed notices shall be addressed to the Plan Administrator, as follows: Senior Vice President, Human Resources, Mallinckrodt Pharmaceuticals, 675 McDonnell Boulevard, Hazelwood, MO 63042, with a copy to the Company’s general counsel,
as follows: Senior Vice President and General Counsel, Mallinckrodt Pharmaceuticals, 675 McDonnell Boulevard, Hazelwood, MO 63042. 
 Section 10.03 Successors. Any successor to the Company shall assume the obligations under this Plan and expressly agree to perform the obligations under this Plan. 

Section 10.04 Other Payments. Except as otherwise provided in this Plan, no Participant shall be entitled to any cash
payments or other benefits under any of the Company’s then-current severance pay policies or plans for a termination that is covered by this Plan. 
 Section 10.05 No Mitigation. Except as otherwise provided in Section 4.04, a Participant shall not be required to mitigate the amount of any Severance Benefits provided for in this
Plan by seeking other employment or otherwise, nor shall the amount of any Severance Benefits provided for herein be reduced by any compensation earned by other employment or otherwise, except if the Participant is re-employed by the Company as an
Employee, in which case Severance Benefits shall cease on the date of the Participant’s re-employment. 

Section 10.06 No Contract of Employment. Neither the establishment of the Plan, nor any modification thereof, nor the
creation of any fund, trust or account, nor the payment of any benefits shall be construed as giving any Eligible Employee or any person whosoever, the right to be retained in the service of the Company, and all Eligible Employees shall remain
subject to discharge to the same extent as if the Plan had never been adopted. 
 Section 10.07 Severability of
Provisions. If any provision of this Plan shall be held invalid or unenforceable by a court of competent jurisdiction, such invalidity or unenforceability shall not affect any other provisions hereof, and this Plan shall be construed and
enforced as if such provisions had not been included. 

  
 -21-

 Section 10.08 Heirs, Assigns, and Personal Representatives. This Plan
shall be binding upon the heirs, executors, administrators, successors and assigns of the parties, including each Participant, present and future. 
 Section 10.09 Headings, Captions and Titles. The titles of the Articles and Sections and the headings and captions herein are provided for reference and convenience only, shall not be
considered part of the Plan or considered in any respect to affect or modify its provisions, and shall not be employed in the construction of the Plan. Such words in this Plan as “herein,” “hereinafter,” “hereof” and
“hereunder” refer to this instrument as a whole and not merely to the subdivision in which said words appear. 

Section 10.10 Gender and Number. Where the context admits: words in any gender shall include any other gender and,
except where otherwise clearly indicated by context, the singular shall include the plural, and vice-versa. 

Section 10.11 Unfunded Plan. The Plan shall not be funded. No Participant shall have any right to, or interest in, any
assets of the Company that may be applied by the Company to the payment of Severance Benefits. 
 Section 10.12
Payments to Incompetent Persons. Any benefit payable to or for the benefit of a minor, an incompetent person or other person incapable of receipting therefor shall be deemed paid when paid to such person’s guardian or to the party
providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Company, the Committee and all other parties with respect thereto. 

Section 10.13 Lost Payees. A Severance Benefit shall be deemed forfeited if the Committee is unable to locate a
Participant to whom Severance Benefits are due. Such Severance Benefits may be reinstated if application is made by the Participant for the forfeited Severance Benefits while this Plan is in operation. 

Section 10.14 Controlling Law. This Plan shall be construed and enforced according to the laws of the State of
Missouri to the extent not superseded by federal law, which shall otherwise control. 

  
 -22-

 Appendix 
 SALARY CONTINUATION AND BONUS PAYMENT SCHEDULE 
 Salary Continuation
Schedule 
  

			
	Chief Executive Officer	  	24 month Severance Period
		
	Executive Vice President and Chief Financial Officer, Senior Vice Presidents and Presidents of business whose annual revenue is $1.5 billion or more	  	18 month Severance Period
		
	Any other Global Business Unit Presidents, any other Officer and any other Eligible Employee	  	12 month Severance Period

 Bonus Payment Schedule 

 

			
	Chief Executive Officer	  	2x Annual Bonus
		
	Executive Vice President and Chief Financial Officer, Senior Vice Presidents and Presidents of business whose annual revenue is $1.5 billion or more	  	1.5x Annual Bonus
		
	Any other Global Business Unit Presidents, any other Officer and any other Eligible Employee	  	1x Annual Bonus

  
 A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]